Universal Beteiligungs und Servicegesellschaft mbH Takes Position in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake of 255,218 shares in ADMA Biologics Inc, valued at approximately $5.06 million, representing 0.11% ownership of the company.
• Several institutional investors have significantly increased their positions in ADMA, with JPMorgan Chase & Co. growing its stake by 272.5% and Sei Investments Co. by 147.2% during the fourth quarter.
• Insider trading activity included the sale of 30,000 shares by directors, collectively valued at over $632,300, indicating a decrease in their ownership stakes.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 255,218 shares of the biotechnology company's stock, valued at approximately $5,064,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.11% of ADMA Biologics as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in ADMA. Tsfg LLC purchased a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $51,000. Farther Finance Advisors LLC grew its stake in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of ADMA Biologics in the 4th quarter valued at approximately $85,000. CIBC Private Wealth Group LLC boosted its stake in shares of ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of ADMA Biologics by 7,038.1% in the fourth quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company's stock valued at $103,000 after buying an additional 5,912 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Up 1.8%

ADMA Biologics stock traded up $0.34 during trading on Thursday, hitting $18.93. The company's stock had a trading volume of 532,491 shares, compared to its average volume of 3,058,832. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of 22.22 and a beta of 0.43. The stock's fifty day moving average is $18.86 and its 200 day moving average is $18.72. ADMA Biologics Inc has a 1-year low of $10.21 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. During the same period last year, the firm posted $0.08 EPS. ADMA Biologics's revenue was up 40.2% on a year-over-year basis. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ADMA. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director owned 94,830 shares in the company, valued at $1,987,636.80. The trade was a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,621 shares of company stock valued at $9,644,269. Insiders own 3.50% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.